Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Accounts Payables (2016 - 2025)

Zevra Therapeutics' Accounts Payables history spans 11 years, with the latest figure at $11.6 million for Q4 2025.

  • For Q4 2025, Accounts Payables fell 54.44% year-over-year to $11.6 million; the TTM value through Dec 2025 reached $11.6 million, down 54.44%, while the annual FY2025 figure was $11.6 million, 54.44% down from the prior year.
  • Accounts Payables reached $11.6 million in Q4 2025 per ZVRA's latest filing, up from $11.1 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $28.4 million in Q4 2023 to a low of $2.1 million in Q3 2021.
  • Average Accounts Payables over 5 years is $11.8 million, with a median of $10.8 million recorded in 2023.
  • Peak YoY movement for Accounts Payables: crashed 55.49% in 2021, then soared 686.57% in 2023.
  • A 5-year view of Accounts Payables shows it stood at $3.0 million in 2021, then rose by 18.86% to $3.6 million in 2022, then skyrocketed by 686.57% to $28.4 million in 2023, then dropped by 10.38% to $25.5 million in 2024, then crashed by 54.44% to $11.6 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Accounts Payables are $11.6 million (Q4 2025), $11.1 million (Q3 2025), and $15.8 million (Q2 2025).